ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015
The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 4 syntheses or guidelines pooled it, 151 citations in OpenAlex.
- The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review.International journal of environmental research and public health · 2018Pooled it
- Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.BMC medical research methodology · 2018Pooled it
- Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis.PloS one · 2017Pooled it
- Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.PharmacoEconomics · 2016Pooled it
- An Electronic Health Record-based Intervention to Promote Hepatitis C Virus Testing Among Adults Born Between 1945 and 1965: A Cluster-randomized Trial.Medical care · 2017Trial
- Informing the Equitable Implementation of Hepatitis C Interventions: Cost-Effectiveness Modeling in Rural Populations of People Who Inject Drugs.PharmacoEconomics · 2026Article
- Hepatitis C in Children-An Asia-Pacific Concise Perspective.Pathogens (Basel, Switzerland) · 2024Review
- Hepatitis C Screening and Antibody Prevalence Among Newly Arrived Refugees to the United States, 2010-2017.Journal of immigrant and minority health · 2023Article
- The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada.PloS one · 2023Article
- Country versus pharmaceutical company interests for hepatitis C treatment.Health care management science · 2022Article
- Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective.BMJ global health · 2020Article
- Drug Costs: What Can Infectious Diseases Physicians Do?The Journal of infectious diseases · 2020Article
- Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine.ClinicoEconomics and outcomes research : CEOR · 2020Article
- Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.Addiction (Abingdon, England) · 2019Article
- Hepatitis C Direct-Acting Antiviral Treatment Selection, Treatment Failure, and Use of Drug-Drug Interactions in a State Medicaid Program.Journal of managed care & specialty pharmacy · 2019Article
- Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up.BMC public health · 2019Article
- DRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS.Journal of health & biomedical law · 2018Article
- Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.Journal of clinical gastroenterology · 2018Observational
- Daclatasvir and asunaprevir improves health-related quality of life in Japanese patients infected with hepatitis C virus.JGH open : an open access journal of gastroenterology and hepatology · 2018Article
- Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States.Current hepatology reports · 2018Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundNew hepatitis C virus (HCV) treatments deliver higher cure rates with fewer contraindications, increasing demand for treatment and healthcare costs. The cost-effectiveness of new treatments is unknown.
methodsWe conducted a microsimulation of guideline testing followed by alternative treatment regimens for HCV among the US population aged 20 and older to estimate cases identified, treated, sustained viral response, deaths, medical costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) of different treatment options expressed as discounted lifetime costs and benefits from the healthcare perspective.
resultsCompared to treatment with pegylated interferon and ribavirin (PR), and a protease inhibitor for HCV genotype (G) 1 and PR alone for G2/3, treatment with PR and Sofosbuvir (PRS) for G1/4 and treatment with Sofosbuvir and ribavirin (SR) for G2/3 increased QALYs by 555 226, reduced deaths by 80 682, and increased costs by $26.2 billion at an ICER of $47 304 per QALY gained. As compared to PRS/SR, treating with an all oral regimen of Sofosbuvir and Simeprevir (SS) for G1/4 and SR for G2/3, increased QALYs by 1 110 451 and reduced deaths by an additional 164 540 at an incremental cost of $80.1 billion and an ICER of $72 169. In sensitivity analysis, where treatment with SS effectiveness was set to the list price of Viekira Pak and then Harvoni, treatment cost $24 921 and $25 405 per QALY gained as compared to PRS/SR.
conclusionsNew treatments are cost-effectiveness per person treated, but pent-up demand for treatment may create challenges for financing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.